Combining Radiotherapy with APO010 in Cancer Treatment
Inge Verbrugge,Esther H.J. Wissink,Rogier W. Rooswinkel,Johan Jongsma,Nicola Beltraminelli,Marc Dupuis,Jannie Borst,Marcel Verheij +7 more
Reads0
Chats0
TLDR
Although APO010 and radiation had a clear combined cytotoxic effect on tumor cells in vitro, a combined therapeutic effect was not achieved on the same cells subcutaneously grafted in mice, atAPO010 doses approximating the maximally tolerable level.Abstract:
Purpose: Various proapoptotic agents are currently being explored to improve the outcome of radiotherapy. We have evaluated whether APO010—a novel recombinant ligand of the Fas/CD95 death receptor—enhanced the cytotoxic effect of radiation on lymphoid and solid tumor cell types. Experimental Design: A Bcl-2–overexpressing T-leukemic cell line (Jurkat), a colon carcinoma cell line (HCT116), and a mesothelioma cell line were used as model systems in vitro and in a subcutaneous transplant setting in immunodeficient mice. Sensitivity to single and combined treatment was read out by apoptosis hallmarks and clonogenic survival in vitro , and by tumor growth delay using bioluminescence and palpation in vivo . Results: Whereas the three cell lines resisted apoptosis induction by irradiation and APO010 alone, combined treatment greatly enhanced their apoptotic response. In clonogenic survival assays, APO010 reduced the outgrowth of Jurkat-Bcl-2 and HCT116 cells and sensitized the mesothelioma cell line to radiation. In vivo , systemic treatment with APO010 alone caused tumor growth delay in Jurkat-Bcl-2 and HCT116 cells. However, APO010 did not improve the efficacy of radiotherapy in any of the model systems at the selected single dose, which had moderate and reversible systemic toxicity. Conclusions: Although APO010 and radiation had a clear combined cytotoxic effect on tumor cells in vitro , a combined therapeutic effect was not achieved on the same cells subcutaneously grafted in mice, at APO010 doses approximating the maximally tolerable level. These findings suggest that it will be difficult to identify a therapeutic window for this combined modality approach in a clinical setting.read more
Citations
More filters
Journal ArticleDOI
Clinical targeting of the TNF and TNFR superfamilies
TL;DR: This Review focuses on the biologics that are currently in clinical trials for immune-related diseases and other syndromes, discusses the successes and failures to date as well as the expanding therapeutic potential of modulating the activity of this superfamily of molecules.
Journal ArticleDOI
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies
Inge Verbrugge,Jim Hagekyriakou,Leslie L. Sharp,Mara Galli,Alison C. West,Nicole McLaughlin,Helene Duret,Hideo Yagita,Ricky W. Johnstone,Mark J. Smyth,Nicole M. Haynes +10 more
TL;DR: Data show that concomitant targeting of immunostimulatory and inhibitory checkpoints with immunomodulatory mAbs can enhance the curative capacity of radiotherapy in established breast malignancy.
Journal ArticleDOI
Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.
TL;DR: In this article, a review summarizes the similarities between growth and immune privilege in cancer and pregnancy and identifies areas for further investigation, and the knowledge gained from analyzing similarities and differences between the physiologic state of pregnancy and the pathology of cancer could lead to identification of new potential targets for cancer therapeutic agents.
Journal ArticleDOI
Death receptors as targets in cancer
TL;DR: A brief review of anti‐tumour therapies based on the use pro‐apoptotic receptor agonists, including TNF‐related apoptosis‐inducing ligand (TRAIL) or monoclonal antibodies targeting TRAIL‐R1 or TRAil‐R2, to provide hints in order to rationally design optimal protocols based on current understanding of TRAIL signalling regulation or resistance for future clinical trials.
Cancer and Pregnancy: Parallels in Growth, Invasion, and Immune Modulation and Implications for Cancer Therapeutic Agents SPECIAL ARTICLE
TL;DR: The knowledge gained from analyzing similarities and differences between the physiologic state of pregnancy and the pathological state of cancer could lead to identification of new potential targets for cancer therapeutic agents.
References
More filters
Journal ArticleDOI
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
TL;DR: A flow cytometric method for measuring the percentage of apoptotic nuclei after propidium iodide staining in hypotonic buffer is developed and shown an excellent correlation with the results obtained with both electrophoretic and colorimetric methods.
Journal ArticleDOI
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
Henning Walczak,Robert E. Miller,Kiley Ariail,Brian Gliniak,Thomas S. Griffith,Marek Kubin,Wilson Chin,Jon Jones,Anne Woodward,Tiep Le,Craig A. Smith,Pam J. Smolak,Raymond G. Goodwin,Charles Rauch,JoAnn C. L. Schuh,David H. Lynch +15 more
TL;DR: Recurrent treatments with LZ–huTRAIL actively suppressed growth of the TRAIL–sensitive human mammary adenocarcinoma cell line MDA–231 in CB.17 (SCID) mice, and histologic examination of tumors from SCID mice treated with Lz–hu TRAIL demonstrated clear areas of apoptotic necrosis within 9–12 hours of injection.
Journal ArticleDOI
Paradoxical roles of the immune system during cancer development
TL;DR: The paradoxical role of adaptive and innate leukocytes as crucial regulators of cancer development is examined and recent insights that have been gained by manipulating immune responses in mouse models of de novo and spontaneous tumorigenesis are highlighted.
Journal ArticleDOI
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi,Roger Pai,Sharon Fong,Susan Leung,David A. Lawrence,Scot A. Marsters,Christine Blackie,Ling Chang,Amy E. McMurtrey,Andrea Hebert,Laura DeForge,Iphigenia Koumenis,Derf Lewis,Louise A. Harris,Jeanine L. Bussiere,Hartmut Koeppen,Zahra Shahrokh,Ralph H. Schwall +17 more
TL;DR: Apo2L may have potent anticancer activity without significant toxicity toward normal tissues, and cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation.
Journal ArticleDOI
Lethal effect of the anti-Fas antibody in mice
Jun Ogasawara,Rie Watanabe-Fukunaga,Masashi Adachi,Akio Matsuzawa,Tsutomu Kasugai,Yukihiko Kitamura,Naoto Itoh,Takashi Suda,Shigekazu Nagata +8 more
TL;DR: The findings suggest that the Fas antigen is important in programmed cell death in the liver, and may be involved in fulminant hepatitis in some cases.
Related Papers (5)
Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site.
Elisabeth Letellier,Sachin Kumar,Ignacio Sancho-Martinez,Stefanie Krauth,Anne Funke-Kaiser,Sabrina Laudenklos,Katrin Konecki,Stefan Klussmann,Nina S. Corsini,Susanne Kleber,Natalia Drost,Andreas Neumann,Matthieu Lévi-Strauss,Benedikt Brors,Norbert Gretz,Lutz Edler,Carmen Fischer,Oliver Hill,Meinolf Thiemann,Bahram Biglari,Saoussen Karray,Ana Martin-Villalba +21 more